The ABPI has today announced the team which will represent the pharmaceutical industry in negotiations with the Department of Health to agree the next medicines pricing scheme from 2014.


​The ABPI is the body recognised  by the Secretary of State for the purposes of negotiating a new voluntary scheme and being consulted on a statutory scheme, as set out in the National Health Service Act 2006.

The negotiations will begin in September and the ABPI has chosen a team which is representative of different sizes of companies as well as the different geographies. 

The team representing the ABPI will be:

  • John Kearney, UK & Ireland General Manager of Amgen.  He will serve as Chair of the team.
  • Pete Butterfield, Executive Director, Alliance.
  • Erik van Snippenberg, General Manager & Senior Vice-President UK, GSK
  • Jon Emms, Managing Director UK, Pfizer
  • Matthew Speers, Managing Director, British and Irish Isles, UCB.

They will be supported by an ABPI team led by Alison Clough, Commercial Director.

Media enquiries

ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064

Notes to editor

  1. The voluntary scheme ( ie the PPRS) is the medicines pricing scheme which is negotiated between industry and Government.

    The statutory scheme is the legislative scheme that controls medicines prices for those companies that choose not to participate in the voluntary scheme.
  2. The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

    Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.

    The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.